恒瑞医药注射用瑞康曲妥珠单抗药物临床试验获批

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SHR-A1811, a drug for HER2-positive breast cancer treatment [1] Group 1: Clinical Trial Approval - The approval allows for a clinical trial comparing SHR-A1811 with a combination of docetaxel, carboplatin, trastuzumab, and pertuzumab for neoadjuvant treatment of early or locally advanced HER2-positive breast cancer [1] Group 2: Mechanism of Action - SHR-A1811 works by binding to HER2-expressing tumor cells and inducing apoptosis through a mechanism involving the release of toxins within the tumor cells' lysosomes [1]